4 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 4 |
Follow Gallbladder Diseases: new trials by email Literature Review of Gallbladder Diseases trials Research Report on Gallbladder Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies STI-3031 - Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma | Phase 2 | Withdrawn | Sorrento Therapeutics, Inc. | 2023-03-01 | 2023-05-01 | |
| Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers Irinotecan & Capecitabine - Biliary Tract Cancer | Phase 2 | Withdrawn | New Mexico Cancer Research Alliance | 2015-11-01 | 2018-01-25 | |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis - Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2013-01-01 | 2014-09-09 | |
| Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer GM-CT-01, 5-Fluorouracil - Cancer of the Bile Duct, Gallbladder Cancer | Phase 2 | Withdrawn | Galectin Therapeutics Inc. | 2006-09-01 | 2017-08-01 |
Gallbladder Neoplasms (4) · Bile Duct Neoplasms (2) · Biliary Tract Neoplasms (2) · Cholangiocarcinoma (2) · Recurrence (2) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Biliary Tract Diseases (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Neoplasms by Site (4) · Adenocarcinoma (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Bile Duct Diseases (2) · Biliary Tract Neoplasms (2) · Carcinoma (2) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
AZD 6244 (1) · Capecitabine (1) · Fluorouracil (1) · IMC-001 (1) · Irinotecan (1) · MK 2206 (1) · Pharmacogenomic Testing (1) · galactomannan (1)
Galectin Therapeutics Inc. (1) · National Cancer Institute (NCI) (1) · New Mexico Cancer Research Alliance (1) · Sorrento Therapeutics, Inc. (1)
United States (2)
Fa-Chyi Lee, MD (1) · Tanios Bekaii-Saab (1)
N01CM00070 (1)